menu
    • menu

    Company profile for Exonate

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Exonateunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Cambridge Innovation Centre Cambridge Science Park Milton Road Cambridge, CB4 ...
    Telephone
    Telephone
    01223 437043
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.exonate.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Exonate to Begin Ph2b Trial of EXN407 for Diabetic Eye Disease
    Exonate to Begin Ph2b Trial of EXN407 for Diabetic Eye Disease

    29 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250728228819/en/Exonate-plans-CLEAR-DE-Phase-IIb-clinical-trial-of-lead-candidate-EXN407-for-diabetic-eye-disease

    BUSINESSWIRE
    29 Jul 2025
    Share Share
    Exonate: Dr. Rafiq Hasan Appointed As Non-Executive Director
    Exonate: Dr. Rafiq Hasan Appointed As Non-Executive Director

    28 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240528389145/en

    BUSINESSWIRE
    28 May 2024
    Share Share
    Exonate launches diabetic macular oedema trial
    Exonate launches diabetic macular oedema trial

    05 Feb 2021

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/exonate_launches_diabetic_macular_oedema_trial_1362699

    Lucy Parsons PHARMATIMES
    05 Feb 2021
    Share Share
    Exonate in collaboration with Janssen patient in ph Ib/II trial for EXN 407
    Exonate in collaboration with Janssen patient in ph Ib/II trial for EXN 407

    02 Feb 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=135237&sid=2

    PHARMABIZ
    02 Feb 2021
    Share Share
    Exonate announces the initiation of Phase Ib/II clinical trial
    Exonate announces the initiation of Phase Ib/II clinical trial

    02 Feb 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/02/02/2167857/0/en/Exonate-announces-the-initiation-of-Phase-Ib-II-clinical-trial-for-Diabetic-Macular-Oedema-as-part-of-its-collaboration-with-Janssen.html#:~:text=CAMBRIDGE%2C%20United%20Kingdom%2C%20Feb.,been%20dosed%20with%20Exonate's%20lead

    GLOBENEWSWIRE
    02 Feb 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search